SURF2 is a MDM2 antagonist in triggering the nucleolar stress response

被引:2
作者
Tagneres, Sophie [1 ]
Santo, Paulo Espirito [1 ]
Radermecker, Julie [2 ]
Rinaldi, Dana [1 ]
Froment, Carine [3 ,4 ]
Provost, Quentin [1 ]
Bongers, Manon [1 ]
Capeille, Solemne [1 ]
Watkins, Nick [5 ]
Marcoux, Julien [3 ,4 ]
Gleizes, Pierre-Emmanuel [1 ]
Marcel, Virginie [2 ]
Plisson-Chastang, Celia [1 ]
Lebaron, Simon [1 ,6 ]
机构
[1] Univ Toulouse, UPS, Mol Cellular & Dev Biol Unit MCD, Ctr Biol Integrat CBI,Team Accreditat French Ligue, 118 Route Narbonne, Toulouse, France
[2] Univ Claude Bernard Lyon 1, Univ Lyon, CNRS UMR5286, Ctr Leon Berard Ctr Rech Cancerol Lyon,INSERM U105, Lyon, France
[3] Univ Toulouse III Paul Sabatier UPS, Univ Toulouse, Inst Pharmacol & Biol Struct IPBS, CNRS, Toulouse, France
[4] ProFI, Infrastructure Natl Prote, Toulouse, France
[5] Newcastle Univ, Med Sch, Biosci Inst, Newcastle Upon Tyne, England
[6] INSERM, Paris, France
关键词
5S RIBOSOMAL-RNA; P53; ACTIVATION; BIOGENESIS; PROTEIN; PRECURSOR; COMPLEX; MYC; L5; INHIBITION; PROMOTER;
D O I
10.1038/s41467-024-52659-x
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Cancer cells rely on high ribosome production to sustain their proliferation rate. Many chemotherapies impede ribosome production which is perceived by cells as "nucleolar stress" (NS), triggering p53-dependent and independent pathways leading to cell cycle arrest and/or apoptosis. The 5S ribonucleoprotein (RNP) particle, a sub-ribosomal particle, is instrumental to NS response. Upon ribosome assembly defects, the 5S RNP accumulates as free form. This free form is able to sequester and inhibit MDM2, thus promoting p53 stabilization. To investigate how cancer cells can resist to NS, here we purify free 5S RNP and uncover an interaction partner, SURF2. Functional characterization of SURF2 shows that its depletion increases cellular sensitivity to NS, while its overexpression promotes their resistance to it. Consistently, SURF2 is overexpressed in many cancers and its expression level is an independent marker of prognosis for adrenocortical cancer. Our data demonstrate that SURF2 buffers free 5S RNP particles, and can modulate their activity, paving the way for the research of new molecules that can finely tune the response to nucleolar stress in the framework of cancer therapies.
引用
收藏
页数:21
相关论文
共 50 条
  • [31] A newly identified Pirh2 substrate SCYL1-BP1 can bind to MDM2 and accelerate MDM2 self-ubiquitination
    Yan, Jing
    Zhang, Di
    Di, Yujun
    Shi, Huili
    Rao, Hai
    Huo, Keke
    FEBS LETTERS, 2010, 584 (15) : 3275 - 3278
  • [32] MDM2 gene amplification and protein expressions in colon carcinoma: is targeting MDM2 a new therapeutic option?
    Hav, Monirath
    Libbrecht, Louis
    Ferdinande, Liesbeth
    Pattyn, Piet
    Laurent, Stephanie
    Peeters, Marc
    Praet, Marleen
    Pauwels, Patrick
    VIRCHOWS ARCHIV, 2011, 458 (02) : 197 - 203
  • [33] Mice with a Mutation in the Mdm2 Gene That Interferes with MDM2/Ribosomal Protein Binding Develop a Defect in Erythropoiesis
    Kamio, Takuya
    Gu, Bai-wei
    Olson, Timothy S.
    Zhang, Yanping
    Mason, Philip J.
    Bessler, Monica
    PLOS ONE, 2016, 11 (04):
  • [34] MDM2 antagonist nutlin-3a sensitizes tumors to V-ATPase inhibition
    Schneider, Lina S.
    Ulrich, Melanie
    Lehr, Thorsten
    Menche, Dirk
    Mueller, Rolf
    von Schwarzenberg, Karin
    MOLECULAR ONCOLOGY, 2016, 10 (07) : 1054 - 1062
  • [35] Reciprocal Induction of MDM2 and MYCN in Neural and Neuroendocrine Cancers
    Tran, Hung N.
    Singh, Hardeep P.
    Guo, Wenxuan
    Cambier, Linda
    Riggan, Luke
    Shackleford, Gregory M.
    Thornton, Matthew E.
    Grubbs, Brendan H.
    Erdreich-Epstein, Anat
    Qi, Dong-Lai
    Cobrinik, David
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [36] Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist
    Wang, Haiyan
    Cai, Shanbao
    Bailey, Barbara J.
    Saadatzadeh, M. Reza
    Ding, Jixin
    Tonsing-Carter, Eva
    Georgiadis, Taxiarchis M.
    Gunter, T. Zachary
    Long, Eric C.
    Minto, Robert E.
    Gordon, Kevin R.
    Sen, Stephanie E.
    Cai, Wenjing
    Eitel, Jacob A.
    Waning, David L.
    Bringman, Lauren R.
    Wells, Clark D.
    Murray, Mary E.
    Sarkaria, Jann N.
    Gelbert, Lawrence M.
    Jones, David R.
    Cohen-Gadol, Aaron A.
    Mayo, Lindsey D.
    Shannon, Harlan E.
    Pollok, Karen E.
    JOURNAL OF NEUROSURGERY, 2017, 126 (02) : 446 - 459
  • [37] Mdm2 Promotes Systemic Lupus Erythematosus and Lupus Nephritis
    Allam, Ramanjaneyulu
    Sayyed, Sufyan G.
    Kulkarni, Onkar P.
    Lichtnekert, Julia
    Anders, Hans-Joachim
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2011, 22 (11): : 2016 - 2027
  • [38] RYBP stabilizes p53 by modulating MDM2
    Chen, Deng
    Zhang, Jianbing
    Li, Mao
    Rayburn, Elizabeth R.
    Wang, Hui
    Zhang, Ruiwen
    EMBO REPORTS, 2009, 10 (02) : 166 - 172
  • [39] Development and Nanoparticle-Mediated Delivery of Novel MDM2/MDM4 Heterodimer Peptide Inhibitors to Enhance 5-Fluorouracil Nucleolar Stress in Colorectal Cancer Cells
    Merlino, Francesco
    Pecoraro, Annalisa
    Longobardi, Giuseppe
    Donati, Greta
    Di Leva, Francesco Saverio
    Brignola, Chiara
    Piccarducci, Rebecca
    Daniele, Simona
    Martini, Claudia
    Marinelli, Luciana
    Russo, Giulia
    Quaglia, Fabiana
    Conte, Claudia
    Russo, Annapina
    La Pietra, Valeria
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (03) : 1812 - 1824
  • [40] Clinical Overview of MDM2/X-Targeted Therapies
    Burgess, Andrew
    Chia, Kee Ming
    Haupt, Sue
    Thomas, David
    Haupt, Ygal
    Lim, Elgene
    FRONTIERS IN ONCOLOGY, 2016, 6